BioNTech SE (BNTX)
| Previous close | 129.64 |
| Open | 128.81 |
| Bid | 131.03 x 800 |
| Ask | 131.27 x 800 |
| Day's range | 128.50 - 131.87 |
| 52-week range | 117.08 - 189.07 |
| Volume | |
| Avg. volume | 694,977 |
| Market cap | 32.521B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 3.18 |
| EPS (TTM) | 41.43 |
| Earnings date | 27 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 June 2022 |
| 1y target est | 216.40 |
- GlobeNewswire
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
BioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3 trial planned to start in 2023BioNTech also plans to combine ONC-392 with its proprietary oncology product candidates to evaluate complementary modes of action with the aim to increase therapeutic effect
- Simply Wall St.
We Ran A Stock Scan For Earnings Growth And BioNTech (NASDAQ:BNTX) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Zacks
Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants
Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.
